A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Inclusion Criteria:

• Stage IV colorectal adenocarcinoma not amenable to curative resection.

• No prior systemic treatment for unresectable or metastatic disease. Participants whoreceived adjuvant or neoadjuvant therapy may enroll if there was no recurrencewithin 12 months of the end of treatment.

• Measurable disease per RECIST v1.1.

• ECOG performance status of 0 or 1.

• Adequate organ function determined by laboratory results.

Exclusion Criteria:

• MSI-H/dMMR per historical data in the medical record.

• BRAF V600E mutation per historical data in the medical record.

• Untreated and/or progressing CNS metastases.

• History of other malignancy within 2 years.

• Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for anyindication within the last 3 years.

• Active autoimmune disease that has required systemic treatment in the past 2 years.

• Significant concurrent and/or uncontrolled medical condition.

• History of organ transplant, including allogeneic stem cell transplantation.

Other protocol-defined inclusion/exclusion criteria apply.